Nuvectis Pharma, Inc.
Formerly Centry Pharma, Inc.
Nuvectis Pharma, Inc. is listed today as Nuvectis Pharma, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2022 | $16 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Nuvectis Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2022).
SEC Form D · Aug 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2022
That is all the official record says: Nuvectis Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Nuvectis Pharma, Inc. are on record.
Investors#
No investor of Nuvectis Pharma, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 19 investors.
Largest shareholders today
Institutions holding Nuvectis Pharma, Inc. shares, as of Sep 30, 2026.
- Soleus Capital Management, L.P.$36 M4.97%
- Tang Capital Management LLC$33 M4.59%
- Braidwell LP$33 M4.58%
- BlackRock, Inc.$28 M3.80%
- Vanguard Capital Management LLC$19 M2.64%
- Iridian Asset Management Llc/ct$17 M2.31%
- Geode Capital Management, LLC$11 M1.46%
- Parkman Healthcare Partners LLC$9 M1.24%
- Baldwin Wealth Partners Llc/ma$8 M1.11%
- State Street Corp$8 M1.07%
- Occam Crest Management LP$8 M1.04%
- Sphera Funds Management LTD.$7 M0.94%
- Schonfeld Strategic Advisors LLC$5 M0.76%
- Perceptive Advisors LLC$5 M0.70%
- Northern Trust Corp$4 M0.50%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Enrique Poradosu | Executive officer | Aug 2022 |
| Michael Carson | Executive officer | Aug 2022 |
| Ron Bentsur | Executive officer | Aug 2022 |
| Shay Shemesh | Executive officer | Aug 2022 |
| James Oliviero | Director | Aug 2022 |
| Kenneth Hoberman | Director | Aug 2022 |
| Matthew Kaplan | Director | Aug 2022 |
| Ron Bentsur | Director | Aug 2022 |
Went public since 2022. Its SEC number is that of a company listed on a stock exchange.